202TiP ASTEFANIA: A phase III study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy

Abstract

T-DM1 is the standard of care for adjuvant treatment of patients (pts) with HER2-positive early breast cancer (eBC) who have invasive residual disease after pre-operative treatment with taxane and HER2-targeted therapy. However a high unmet need remains in some higher risk subgroups (eg, inoperable or lymph node-positive, hormone receptor-negative disease) who have 3-year invasive disease-free survival (IDFS) rates of 76%. Exploratory analyses suggest that addition of the PD-L1 inhibitor atezolizumab to T-DM1 results in longer progression-free survival compared to T-DM1 alone in pts with previously treated PD-L1-positive metastatic BC.